Education
About Us
Working with TipRanks
Follow Us
Edgewise Therapeutics (EWTX)
NASDAQ:EWTX
EWTX Stock Chart & Stats
$28.17
-$0.39(-1.54%)
At close: 4:00 PM EST
$28.17
-$0.39(-1.54%)
Day’s Range― - ―
52-Week Range$10.60 - $30.48
Previous CloseN/A
Volume107.81K
Average Volume (3M)1.59M
Market Cap
$2.98B
Enterprise Value$1.15B
Total Cash (Recent Filing)$563.34M
Total Debt (Recent Filing)$4.18M
Price to Earnings (P/E)―
Beta2.37
Next Earnings
Feb 19, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding105,868,430
10 Day Avg. Volume826,007
30 Day Avg. Volume1,590,345
Financial Highlights & Ratios
PEG Ratio2.41
Price to Book (P/B)5.37
Price to Sales (P/S)0.00
P/FCF Ratio-22.36
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-6.68
Forecast
1Y Price Target
$38.14Price Target Upside35.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Program AdvancementCompletion of Phase 2 CIRRUS-HCM Parts B and C together with strong enrollment in Part D positions EDG-7500 for continued development, and the forthcoming 12-week Part D dataset is expected to inform Phase 3 trial design.
Financial FlexibilityA strong cash position supports continued advancement of both late-stage and early-stage programs, reducing near-term financing pressure and enabling execution of upcoming clinical milestones.
Pipeline Expansion — Becker Muscular DystrophySevasemten has shown encouraging functional benefits in prior studies and could become the first approved therapy for Becker muscular dystrophy, creating a meaningful new market opportunity for the company.
Bears Say
Cardiac Safety SignalNew-onset atrial fibrillation cases reported in the Part D cohort raise concerns about EDG-7500's cardiac safety and increase uncertainty until longer-term safety data are available.
Competitive Differentiation RiskIntroduction of a dose titration regimen undermines an earlier differentiation claim for EDG-7500 and complicates competitive positioning versus other cardiac myosin inhibitors.
Pivotal Readout UncertaintyUnresolved safety questions are tempering expectations for the Phase 3 Becker muscular dystrophy readout in 2026, which could limit near-term upside from the pivotal data.
Edgewise Therapeutics News
EWTX FAQ
What was Edgewise Therapeutics’s price range in the past 12 months?
Edgewise Therapeutics lowest stock price was $10.60 and its highest was $30.48 in the past 12 months.
What is Edgewise Therapeutics’s market cap?
Edgewise Therapeutics’s market cap is $2.98B.
When is Edgewise Therapeutics’s upcoming earnings report date?
Edgewise Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 35 days.
How were Edgewise Therapeutics’s earnings last quarter?
Edgewise Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.397 by $0.007.
Is Edgewise Therapeutics overvalued?
According to Wall Street analysts Edgewise Therapeutics’s price is currently Undervalued.
Does Edgewise Therapeutics pay dividends?
Edgewise Therapeutics does not currently pay dividends.
What is Edgewise Therapeutics’s EPS estimate?
Edgewise Therapeutics’s EPS estimate is -0.44.
How many shares outstanding does Edgewise Therapeutics have?
Edgewise Therapeutics has 105,868,430 shares outstanding.
What happened to Edgewise Therapeutics’s price movement after its last earnings report?
Edgewise Therapeutics reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.397. Following the earnings report the stock price went down -1.612%.
Which hedge fund is a major shareholder of Edgewise Therapeutics?
Currently, no hedge funds are holding shares in EWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edgewise Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.14 (35.39% Upside)
$38.14 (35.39% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.50%
12-Months-Change
Fundamentals
Return on Equity
-30.02%
Trailing 12-Months
Asset Growth
14.12%
Trailing 12-Months
Company Description
Edgewise Therapeutics
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
EWTX Stock 12 Month Forecast
Average Price Target
$38.14
▲(35.39% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
1.39% Insiders
11.37% Mutual Funds
75.37% Other Institutional Investors
3.35% Public Companies and
Individual Investors